Jan 17, 2023
AIM ImmunoTech Enters into Pancreatic Cancer Clinical Research Agreements with AstraZeneca and Erasmus Medical Center
Jan 09, 2023
AIM ImmunoTech Broadens Patent Portfolio with New Netherlands Utility Patent Covering Ampligen® and Other AIM-Developed dsRNA Products to Include Rugged dsRNA for Use in COVID-19 Treatment or Prevention
Jan 05, 2023
AIM ImmunoTech to Present at the 'Virtual Investor 2023 Companies to Watch Event'
Dec 12, 2022
AIM ImmunoTech Appoints Christopher McAleer, Ph.D. as Scientific Officer
Dec 08, 2022
AIM ImmunoTech Reports Positive Safety, Tolerability and Biological Activity Data for Intranasal Ampligen® (Rintatolimod) in Healthy Subjects
Dec 02, 2022
AIM ImmunoTech Announces Abstract Accepted for Poster Presentation at the British Society for Immunology Congress 2022
Nov 15, 2022
AIM ImmunoTech Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Nov 14, 2022
AIM ImmunoTech Announces Presentation of New Data from Roswell Park Comprehensive Cancer Center Evaluating Ampligen® as a Component of a Chemokine-Modulating (CKM) Regimen, with Paclitaxel, for the Treatment of Early-Stage Triple Negative Breast Cancer
Nov 09, 2022
AIM ImmunoTech Announces Corporate Governance Enhancements
Nov 03, 2022
AIM ImmunoTech Shareholders Elect All Three Company Director Nominees at 2022 Annual Meeting
 2   3   4   5   6     7    8   9   10   11   12 
 <<   <   >   >>